Developmental Research Program
发展研究计划
基本信息
- 批准号:10210204
- 负责人:
- 金额:$ 8.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-07-10 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:American Cancer SocietyAwardClinical ResearchCollaborationsDevelopmentEvolutionExtramural ActivitiesFosteringFoundationsFundingFutureGoalsGrantHead and Neck CancerInstitutesInstitutionMalignant NeoplasmsMalignant neoplasm of lungMedicalMonitorNatureOutcomePatient CarePeer ReviewPeer Review GrantsPilot ProjectsProcessProgram Research Project GrantsPublicationsRequest for ProposalsResearchResearch PersonnelResearch Project GrantsResearch ProposalsSeriesSourceTranslational ResearchUnited States National Institutes of HealthUniversitiesanticancer researchcareer developmenthigh rewardhigh riskinnovationnovelpreclinical studyprogramssuccesstranslational study
项目摘要
PROJECT SUMMARY/ABSTRACT
Emory University’s Lung Cancer SPORE aims to pursue new and innovative research opportunities in the lung
cancer field through the implementation of the Developmental Research Program (DRP). The DRP will solicit,
evaluate, and fund the most meritorious pilot projects, monitor progress twice annually, and promote the most
successful pilot projects into full projects funded by the SPORE and/or other sources. The goals of the DRP
are to identify and support meritorious proposals that might expand into full research projects focused on lung
cancer in the future, including those of high risk-high reward projects that might otherwise not be funded; to
foster collaborative research between Emory investigators and investigators at other institutions; and to
enhance translational research in lung cancer by increasing the number of investigators working in this field.
The Winship Cancer Institute (Winship) of Emory University has a strong track record in conducting successful
pilot project programs. Through the Winship Invest$ program, Winship has awarded 165 pilot grants, with a
total of over $7.7M in funding, since 2012. Our track record is illustrated by the DRP in Emory’s head and neck
cancer SPORE (funded from 2006-2013) that awarded 17 pilot projects, which evolved into 15 full projects
funded by NIH or foundations such as the American Cancer Society and the publication of 34 research articles
and 4 review articles. Winship is also a recipient of the ‘Institutional Research Grant’ funded by the American
Cancer Society that supports pilot research projects. Specific aims for the DRP are as follows: Aim 1: To
solicit research proposals by sending request for proposals (RFP) to all possible applicants at Emory
University and other research and medical institutions throughout the state of Georgia; Aim 2: To identify the
most outstanding and novel proposals to fund through a clearly defined and well-established review process.
Led by a DRP Committee, applications will be reviewed by a panel of leaders of all projects, cores/programs,
and other researchers in relevant fields, following NIH review criteria; and Aim 3: To monitor the progress of
funded peer-reviewed pilot projects using a series of metrics, including the evolution of projects into major
projects (e.g., R01s, full SPORE projects), publications, investigator career development etc. We expect that
annually 2 novel projects in basic, translational and clinical studies will be funded, and completion of these
high-risk but innovative studies will result in strong publications, additional peer-reviewed grants and the
development of a larger and stronger group of investigators focusing on the translational study of lung cancer.
项目摘要/摘要
埃默里大学的肺癌孢子致力于在肺部寻求新的创新研究机会
通过实施发展研究计划(DRP),在癌症领域取得进展。DRP会征集,
评估、资助最有功绩的试点项目,每年两次监测进展,最大限度地推动
成功的试点项目转变为由孢子和/或其他来源资助的全面项目。DRP的目标
是确定和支持有价值的建议,这些建议可能会扩展为以肺部为重点的全面研究项目
未来的癌症,包括那些本来可能得不到资助的高风险、高回报的项目;
促进埃默里调查人员和其他机构的调查人员之间的合作研究;以及
通过增加在该领域工作的研究人员的数量来加强肺癌的转译研究。
埃默里大学的温希普癌症研究所(Winship)在开展成功的
试点项目方案。通过Winship Invest$计划,Winship已授予165项试点拨款,其中
自2012年以来,总共获得了超过770万美元的资金。我们的记录可以通过埃默里头部和颈部的DRP来说明
癌症孢子(2006-2013年资助),授予17个试点项目,这些项目演变为15个完整项目
由美国国立卫生研究院或美国癌症协会等基金会资助,发表了34篇研究文章
4篇综述文章。温希普还获得了由美国政府资助的“机构研究补助金”。
支持试点研究项目的癌症协会。发展政策方案的具体目标如下:目标1:
通过向埃默里学院所有可能的申请者发送征求建议书(RFP)来征求研究建议书
乔治亚州的大学和其他研究和医疗机构;目标2:确定
通过明确界定和完善的审查程序为最杰出和最新颖的提案提供资金。
由DRP委员会领导的申请将由所有项目、核心/计划的领导人组成的小组进行审查,
和相关领域的其他研究人员,遵循美国国立卫生研究院的审查标准;以及目标3:监测
使用一系列衡量标准资助同行评审的试点项目,包括将项目演变为主要项目
项目(例如,R01、全孢子项目)、出版物、调查员职业发展等。我们期望
每年将资助2个基础、翻译和临床研究方面的新项目,并完成这些项目
高风险但创新的研究将产生强有力的出版物、额外的同行审查赠款和
发展一个更大、更强大的研究小组,专注于肺癌的转化性研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HAIAN FU其他文献
HAIAN FU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HAIAN FU', 18)}}的其他基金
Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD)
解读肺腺癌 (LUAD) 中 LKB1 相关免疫治疗耐药性
- 批准号:
10411665 - 财政年份:2022
- 资助金额:
$ 8.98万 - 项目类别:
Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD)
解读肺腺癌 (LUAD) 中 LKB1 相关免疫治疗耐药性
- 批准号:
10631134 - 财政年份:2022
- 资助金额:
$ 8.98万 - 项目类别:
Project 2: Reversing STING-mediated immunosuppression in LKB1-mutant lung adenocarcinoma
项目 2:逆转 LKB1 突变型肺腺癌中 STING 介导的免疫抑制
- 批准号:
10631142 - 财政年份:2022
- 资助金额:
$ 8.98万 - 项目类别:
Project 2: Reversing STING-mediated immunosuppression in LKB1-mutant lung adenocarcinoma
项目 2:逆转 LKB1 突变型肺腺癌中 STING 介导的免疫抑制
- 批准号:
10411667 - 财政年份:2022
- 资助金额:
$ 8.98万 - 项目类别:
相似海外基金
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 8.98万 - 项目类别:
IGF::OT::IGF PURPOSE: TO AWARD THE BASE PERIOD FOR CLINICAL RESEARCH COORDINATING CENTER FOR THE NIDA CTN POP: 08/14/2015-08/13/2016.
IGF::OT::IGF 目的:授予 NIDA CTN POP 临床研究协调中心基期:2015 年 8 月 14 日至 2016 年 8 月 13 日。
- 批准号:
9288087 - 财政年份:2015
- 资助金额:
$ 8.98万 - 项目类别:
K30: Clinical Research Curriculum Award - WMC
K30:临床研究课程奖 - WMC
- 批准号:
6846424 - 财政年份:2005
- 资助金额:
$ 8.98万 - 项目类别: